Edition:
United Kingdom

Minerva Neurosciences Inc (NERV.OQ)

NERV.OQ on NASDAQ Stock Exchange Global Market

7.20USD
20 Apr 2018
Change (% chg)

-- (--)
Prev Close
$7.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
47,272
52-wk High
$11.15
52-wk Low
$4.90

Chart for

About

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment... (more)

Overall

Beta: --
Market Cap(Mil.): $320.94
Shares Outstanding(Mil.): 42.51
Dividend: --
Yield (%): --

Financials

  NERV.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -1.08 -- --
ROI: -30.23 1.58 14.38
ROE: -34.99 2.41 16.07

BRIEF-Minerva Neurosciences Screens First Patient In Phase 2B Trial Of Min 117 To Treat Major Depressive Disorder

* MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 2B TRIAL OF MIN 117 TO TREAT MAJOR DEPRESSIVE DISORDER

09 Apr 2018

BRIEF-Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter And Year End Financial Results

* MINERVA NEUROSCIENCES REPORTS FISCAL 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS AND BUSINESS UPDATES

12 Mar 2018

BRIEF-Minerva Neurosciences Names Remy Luthringer As Executive Chairman

* MINERVA NEUROSCIENCES NAMES REMY LUTHRINGER AS EXECUTIVE CHAIRMAN AND WILLIAM DOYLE AS LEAD INDEPENDENT DIRECTOR

05 Feb 2018

BRIEF-Minerva Neurosciences Names Remy Luthringer As Executive Chairman

* MINERVA NEUROSCIENCES NAMES REMY LUTHRINGER AS EXECUTIVE CHAIRMAN AND WILLIAM DOYLE AS LEAD INDEPENDENT DIRECTOR

05 Feb 2018

BRIEF-Minerva Neurosciences Screens First Patient In Phase 3 Trial Of MIN-101 To Treat Negative Symptoms In Schizophrenia

* MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 3 TRIAL OF MIN-101 TO TREAT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA

19 Dec 2017

BRIEF-Minerva Neurosciences Screens First Patient In Phase 3 Trial Of Schizophrenia Drug

* MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 3 TRIAL OF MIN-101 TO TREAT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA Source text for Eikon: Further company coverage:

19 Dec 2017

BRIEF-Minerva Neurosciences names Richard Russell president

* MINERVA NEUROSCIENCES INC - REMY LUTHRINGER WILL CONTINUE AS CHIEF EXECUTIVE OFFICER OF MINERVA WHILE RESIGNING HIS POSITION AS PRESIDENT Source text for Eikon: Further company coverage:

11 Dec 2017

BRIEF-Minerva Neurosciences reports Q3 loss per share $0.28

* Minerva Neurosciences Inc reports third quarter 2017 financial results and business updates

06 Nov 2017

Competitors

Earnings vs. Estimates